Medical disease-modifying treatments are lacking in Parkinson’s disease (PD). Physical exercise is potentially an inexpensive and easily accessible disease-modifying therapy, but this remains to be studied using recent promising magnetic resonance imaging (MRI) markers of disease progression. The objective was to determine whether 24 weeks of moderate to high-intensity progressive aerobic exercise affects brain MRI measures in people with PD (pwPD).
Methods:
A 24-week randomized controlled multicenter trial (with a 24-week follow-up) was conducted, including an exercise group (supervised aerobic exercise followed by self-guided physical activity) and a control group (habitual lifestyle). Patients older than 40 years with mild to moderate impairments (Hoehn & Yahr score ≤3) were randomized (1:1). The primary outcome was R2* (effective transverse relaxation rate) after 24 weeks, which was analyzed using the intention-to-treat principle. Additional outcomes included free water and neuromelanin levels in the substantia nigra, cardiorespiratory fitness, the Movement Disorder Society-sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), and levodopa equivalent daily dose (LEDD).
Results:
Seventy participants were randomized to exercise (n = 36) or control (n = 34). R2* did not change over the intervention period (between-group difference: −1.14 [−5.14; 2.87], mean [95%CI]). Similarly, no significant effects were seen in cardiorespiratory fitness (+1.64 mL O2/min/kg [−0.23; 3.51]) and MDS-UPDRS III (−0.7 [−5.3; 4.0]), whereas LEDD increased less following exercise (−78.4 [−154.6; −2.1]).
Conclusion:
These findings do not support a neuroprotective effect of progressive aerobic exercise on R2* in pwPD, whereas the intervention appears to benefit the efficacy of levodopa.
JennerPMorrisHRRobbinsTW, et al. Parkinson’s disease–the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis. 2013;3(1):1-11.
2.
AthaudaDFoltynieT.The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol. 2015;11(1):25-40.
3.
HenchcliffeCSevertWL.Disease modification in Parkinson’s disease. Drugs Aging. 2011;28(8):605-615.
4.
BurciuRGOforiEArcherDB, et al. Progression marker of Parkinson’s disease: a 4-year multi-site imaging study. Brain. 2017;140(8):2183-2192.
5.
UllaMBonnyJMOuchchaneLRieuIClaiseBDurifF.Is R2* a new MRI biomarker for the progression of Parkinson’s disease? A longitudinal follow-up. PLoS ONE. 2013;8(3):e57904.
6.
HopesLGrolezGMoreauC, et al. Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson’s disease stages?PLoS ONE. 2016;11(4):e0147947.
7.
AnHZengXNiuT, et al. Quantifying iron deposition within the substantia nigra of Parkinson’s disease by quantitative susceptibility mapping. J Neurol Sci. 2018;386:46-52.
8.
HuddlestonDELangleyJSedlacikJBoelmansKFactorSAHuXP.In vivo detection of lateral-ventral tier nigral degeneration in Parkinson’s disease. Hum Brain Mapp. 2017;38(5):2627-2634.
9.
LangleyJHuddlestonDESedlacikJBoelmansKHuXP.Parkinson’s disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta. Mov Disord. 2017;32(3):441-449.
10.
SchwarzSTXingYTomarPBajajNAuerDP.In vivo assessment of brainstem depigmentation in parkinson disease: potential as a severity marker for multicenter studies. Radiology. 2017;283(3):789-798.
11.
FabbriMReimaoSCarvalhoM, et al. Substantia nigra neuromelanin as an imaging biomarker of disease progression in Parkinson’s disease. J Parkinsons Dis. 2017;7(3):491-501.
12.
GalganiALombardoFDella LattaD, et al. Locus coeruleus magnetic resonance imaging in neurological diseases. Curr Neurol Neurosci Rep. 2020;21(1):2.
13.
AhlskogJE.Aerobic exercise: evidence for a direct brain effect to slow parkinson disease progression. Mayo Clin Proc. 2018;93(3):360-372.
14.
de LaatBHoyeJStanleyG, et al. Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease. NPJ Parkinsons Dis. 2024;10(1):34.
15.
JohanssonMECameronIGMvan der KolkNM, et al. Aerobic exercise alters brain function and structure in Parkinson’s disease a randomized controlled trial. Ann Neurol. 2022;91(2):203-216.
16.
van der KolkNMde VriesNMKesselsRPC, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. Lancet Neurol. 2019;18(11):998-1008.
17.
SchenkmanMMooreCGKohrtWM, et al. Effect of high-intensity treadmill exercise on motor symptoms in patients with De Novo Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2018;75(2):219-226.
18.
Langeskov-ChristensenMFranzenEGrondahl HvidLDalgasU.Exercise as medicine in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2024;95(11):1077-1088.
19.
LaHueSCComellaCLTannerCM.The best medicine? The influence of physical activity and inactivity on Parkinson’s disease. Mov Disord. 2016;31(10):1444-1454.
20.
HirschMAIyerSSSanjakM.Exercise-induced neuroplasticity in human Parkinson’s disease: what is the evidence telling us?Parkinsonism Relat Disord. 2016;22 Suppl 1:S78-S81.
21.
ZigmondMJSmeyneRJ.Exercise: is it a neuroprotective and if so, how does it work?Parkinsonism Relat Disord. 2014;20 Suppl 1:S123-S127.
22.
HirschMAvan WegenEEHNewmanMAHeynPC.Exercise-induced increase in brain-derived neurotrophic factor in human Parkinson’s disease: a systematic review and meta-analysis. Transl Neurodegener. 2018;7:7.
23.
FrazzittaGMaestriRGhilardiMF, et al. Intensive rehabilitation increases BDNF serum levels in parkinsonian patients: a randomized study. Neurorehabil Neural Repair. 2014;28(2):163-168.
24.
AngelucciFPiermariaJGelfoF, et al. The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects. Can J Physiol Pharmacol. 2016;94(4):455-461.
25.
UhrbrandAStenagerEPedersenMSDalgasU.Parkinson’s disease and intensive exercise therapy–a systematic review and meta-analysis of randomized controlled trials. J Neurol Sci. 2015;353(1-2):9-19.
26.
NiMSignorileJFBalachandranAPotiaumpaiM.Power training induced change in bradykinesia and muscle power in Parkinson’s disease. Parkinsonism Relat Disord. 2016;23:37-44.
27.
NiMSignorileJFMooneyK, et al. Comparative effect of power training and high-speed yoga on motor function in older patients with parkinson disease. Arch Phys Med Rehabil. 2016;97(3):345-54.e15.
28.
WuPLLeeMHuangTT.Effectiveness of physical activity on patients with depression and Parkinson’s disease: a systematic review. PLoS ONE. 2017;12(7):e0181515.
29.
ChungCLThilarajahSTanD.Effectiveness of resistance training on muscle strength and physical function in people with Parkinson’s disease: a systematic review and meta-analysis. Clin Rehabil. 2016;30(1):11-23.
30.
DuchesneCLunguONadeauA, et al. Enhancing both motor and cognitive functioning in Parkinson’s disease: aerobic exercise as a rehabilitative intervention. Brain Cogn. 2015;99:68-77.
31.
FlachAJaegersLKriegerM, et al. Endurance exercise improves function in individuals with Parkinson’s disease: a meta-analysis. Neurosci Lett. 2017;659:115-119.
32.
CarvalhoABarbiratoDAraujoN, et al. Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson’s disease: pilot study. Clin Interv Aging. 2015;10:183-191.
33.
HazamyAAAltmannLJPStegemollerE, et al. Improved cognition while cycling in Parkinson’s disease patients and healthy adults. Brain Cogn. 2017;113:23-31.
34.
Silva-BatistaCCorcosDMRoschelH, et al. Resistance Training with Instability for Patients with Parkinson’s Disease. Med Sci Sports Exerc. 2016;48(9):1678-87.
35.
PicelliAVaraltaVMelottiC, et al. Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson’s disease: a pilot, single-blind, randomized controlled trial. Funct Neurol. 2016;31(1):25-31.
36.
GamborgMHvidLGDalgasULangeskov-ChristensenM.Parkinson’s disease and intensive exercise therapy–an updated systematic review and meta-analysis. Acta Neurol Scand. 2022;145(5):504-528.
37.
HopewellSChanAWCollinsGS, et al. CONSORT 2025 statement: updated guideline for reporting randomized trials. Nat Med. 2025;31(6):1776-1783.
38.
Bonde-JensenFDalgasULangeskov-ChristensenM.Are physical activity levels, cardiorespiratory fitness and peak power associated with Parkinson’s disease severity?J Neurol Sci. 2024;460:122996.
39.
GoetzCGTilleyBCShaftmanSR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170.
40.
JensenFBDalgasUBrincksJLangeskov-ChristensenM.Validity and reliability of VO(2)-max testing in persons with Parkinson’s disease. Parkinsonism Relat Disord. 2023;109:105324.
41.
ClarkeCLTaylorJCrightonLJGoodbrandJAMcMurdoMETWithamMD.Validation of the AX3 triaxial accelerometer in older functionally impaired people. Aging Clin Exp Res. 2017;29(3):451-457.
42.
BaeckeJABuremaJFrijtersJE.A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36(5):936-942.
43.
PetoVJenkinsonCFitzpatrickR.PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol. 1998;245 Suppl1:S10-S14.
44.
JostSTKaldenbachMAAntoniniA, et al. Levodopa dose equivalency in Parkinson’s disease: updated systematic review and proposals. Mov Disord. 2023;38(7):1236-1252.
45.
HarringtonDD’AgostinoRBSr.GatsonisC, et al. New guidelines for statistical reporting in the journal. N Engl J Med. 2019;381(3):285-286.
46.
AmrheinVGreenlandSMcShaneB.Scientists rise up against statistical significance. Nature. 2019;567(7748):305-307.
47.
FeinsteinAAmatoMPBrichettoG, et al. Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial. Lancet Neurol. 2023;22(10):912-924.
48.
Di LucaDGRamirez-GomezCSantyrB, et al. Clinical and imaging correlates of medication reduction in globus pallidus stimulation for Parkinson’s disease. Mov Disord Clin Pract. 2025;12(7):985-990.
49.
LuthraNSMehtaNMunozMJ, et al. Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease. NPJ Parkinsons Dis. 2025;11(1):190.
50.
WilsonACPountneyDLKhooTK.Therapeutic mechanisms of exercise in Parkinson’s disease. Int J Mol Sci. 2025;26(10):4860.
